Yoshikazu Mutoh
A5040745239- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Respiratory viral infections research
- Nosocomial Infections in ICU
- Antifungal resistance and susceptibility
- Antibiotic Use and Resistance
- Diabetes and associated disorders
- Infection Control in Healthcare
- Respiratory Support and Mechanisms
- Pneumonia and Respiratory Infections
- Erythrocyte Function and Pathophysiology
- Single-cell and spatial transcriptomics
- Blood groups and transfusion
- Hemoglobinopathies and Related Disorders
- Antibiotic Resistance in Bacteria
- Pharmacovigilance and Adverse Drug Reactions
- Enterobacteriaceae and Cronobacter Research
- Influenza Virus Research Studies
- Clostridium difficile and Clostridium perfringens research
- Fungal Infections and Studies
- Urinary Tract Infections Management
- Infectious Diseases and Tuberculosis
- interferon and immune responses
Tosei General Hospital
2019-2025
Fujita Health University
2023
Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that approved for treatment influenza in Japan. We conducted a prospective, randomized, open-label, multicenter trial favipiravir the COVID-19 at 25 hospitals across Eligible patients were adolescents and adults admitted with who asymptomatic or mildly ill had Eastern Cooperative Oncology Group (ECOG) performance status 0 1. Patients randomly assigned 1:1 ratio to early late therapy (in latter case, same...
We aimed to elucidate differences in the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization Japan, by COVID-19 waves, from conventional strains Delta variant.We used secondary data a database and performed retrospective cohort study that included 3261 aged ≥ 18 years enrolled 78 hospitals participated Japan Task Force between February 2020 September 2021.Patients hospitalized during second (mean age, 53.2 [standard deviation {SD}, ± 18.9]) fifth...
The coronavirus disease (COVID-19) pandemic is having a devastating effect worldwide. Host genome differences between populations may influence the severity of COVID-19. Japan COVID-19 Task Force conducting host analysis hospitalized patients with from more than 70 institutions nationwide in Japan. This report describes clinical characteristics enrolled to date. median (interquartile range) age 1674 included was 59 (45-71) years, and half (66.2%) were male. Less (41.2%) had severe disease....
Abstract Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious that has caused millions of deaths, where comprehensive understanding mechanisms still unestablished. In particular, studies gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on thorough analysis whole blood RNA-seq data from 465 genotyped samples the Japan Task Force, including 359 severe 106 non-severe cases. We discover 1169 putative causal...
Abstract Background Respiratory symptoms are associated with coronavirus disease 2019 (COVID-19) outcomes. However, the impacts of upper and lower respiratory on COVID-19 outcomes in same population have not been compared. The objective this study was to characterize compare their hospitalized patients. Methods This a multicenter, retrospective cohort study; database from Japan Task Force used. A total 3314 patients were included study, data collected. participants classified according...
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults those at high risk of disease progression. This retrospective single-center observational study assessed compared outcomes COVID-19 treated MOV NMV/r a real-world community setting. We included confirmed combined one or more factors progression from June to October 2022. Of 283...
Although cases of respiratory bacterial infections associated with coronavirus disease 2019 (COVID-19) have often been reported, their impact on the clinical course remains unclear. Herein, we evaluated and analyzed complication rates infections, causative organisms, patient backgrounds, outcome in Japanese patients COVID-19.We performed a retrospective cohort study that included inpatients COVID-19 from multiple centers participating Japan Taskforce (April 2020 to May 2021) obtained...
This study aimed to identify the relationship between abnormal serum uric acid levels or a history of hyperuricemia and COVID-19 severity in Japanese population.We included 1523 patients enrolled Japan Task Force cohort February 2020 May 2021. We compared clinical characteristics, including co-morbidities, laboratory findings, outcomes, particularly invasive mechanical ventilation (IMV), among with without hyperuricemia.Patients high were older had higher body weight mass index than those...
Abstract Background Obesity is reported to be a risk factor for severe disease in patients with coronavirus 2019 (COVID-19). However, there are no specific reports on the of according body mass index (BMI) Japan. Thus, this study aimed investigate effect obesity stratified by BMI severity COVID-19 general Japanese population. Methods From February 2020 May 2021, 1 837 aged ≥18 years were enrolled Japan Task Force. Patients known and analyzed. Severity was defined as critical if patient...
Abstract To elucidate the host genetic loci affecting severity of SARS-CoV-2 infection, or Coronavirus disease 2019 (COVID-19), is an emerging issue in face current devastating pandemic. Here, we report a genome-wide association study (GWAS) COVID-19 Japanese population led by Japan Task Force, as one initial discovery GWAS studies performed on non-European population. Enrolling total 2,393 cases and 3,289 controls, not only replicated previously reported risk variants (e.g., LZTFL1, FOXP4,...
Smoking and chronic obstructive pulmonary disease (COPD) are risk factors for severe COVID-19. However, limited literature exists on the effect of COPD smoking COVID-19 outcomes. This study examined impact exposure in pack-years (PY) outcomes among smokers Japan.The included 1266 enrolled by Japan task force between February 2020 December 2021. PY status was self-reported patients. Patients were classified into non-COPD (n = 1151) 115) groups; group further <10 293), 10-30 497), >30 361)....
The aging of patients with tuberculosis and better therapeutic management for them are recent concerns. This study aimed to identify risk factors adverse drug reactions (ADRs) or death in very elderly pulmonary assess the association between dosage antituberculosis drugs outcomes. We conducted a multicenter retrospective at two hospitals. Hospitalized (≥ 80 years old) who were treated enrolled. Multivariate analysis was performed associated ADRs within 60 days after treatment initiation. In...
Ruminococcus gnavus , a Gram-positive anaerobic coccus, is common constituent of the human gut microbiota but rarely causes any disease in humans. Herein, we report case R. bacteraemia an immunocompromised 73-year-old man with sigmoid colon perforation. usually reported as diplococci or short chains on Gram staining; however, our patient, blood isolate showed cocci long chains, and organisms from subculture morphological diversity. This provides insight into diversity which might help...
Kluyvera ascorbata is a gram-negative, catalase-positive, oxidase-negative, aerobic fermentative bacterium with flagella. This organism colonizes in the human body and its pathogenicity extremely low; few clinical cases of K. infection have been reported.We report on patient who experienced severe sepsis acute cholangitis due to bacteremia was treated levofloxacin following antibiotic susceptibility testing. To our knowledge, this first case third-generation cephalosporins resistant...
Baloxavir marboxil (baloxavir) is a new anti-influenza virus agent that comparable to oseltamivir phosphate (oseltamivir). Since the efficacy of baloxavir in preventing household transmission influenza not well established, we compared secondary rates between patients on vs oseltamivir.Between October 2018 and March 2019, enrolled index (diagnosed with treated or oseltamivir) members. The attack rate members was oseltamivir. Risk factors were determined using multivariate logistic...
The clinical course of coronavirus disease (COVID-19) is diverse, and the usefulness phenotyping in predicting severity or prognosis has been demonstrated overseas. This study aimed to investigate clinically meaningful phenotypes Japanese COVID-19 patients using cluster analysis.From April 2020 May 2021, data from inpatients aged ≥ 18 years diagnosed with who agreed participate were collected. A total 1322 included. Hierarchical analysis was performed variables reported be associated...
There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated administration COVID-19 estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between March 2020 and April 2022 at Tosei General Hospital, Japan. Propensity score matching performed eGFR ≤ 30 mL/min >30 administration. The primary outcome 30-day mortality after first Adverse events, including development acute injury (AKI),...
To determine the effectiveness of baricitinib in patients with coronavirus disease 2019 (COVID-19), investigate whether prevents need for invasive mechanical ventilation and identify patient subgroups that would benefit from baricitinib. This observational matched-cohort study was conducted by Japan COVID-19 Task Force, a nationwide multicenter consortium. Patients aged ≥18 years were identified 70 hospitals Japan. Among confirmed February 2020 to September 2021, those receiving...